Graham Parry
Stock Analyst at Citi
(2.24)
# 2,949
Out of 4,334 analysts
219
Total ratings
58.6%
Success rate
0.6%
Average return
Main Sectors:
Stocks Rated by Graham Parry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | $275 → $290 | $289.00 | +0.35% | 5 | May 12, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | $23 → $21 | $1,915.00 | -98.90% | 50 | May 6, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | n/a | $13,916.00 | - | 5 | Apr 30, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Buy | n/a | $119.46 | - | 49 | Apr 13, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Buy | n/a | $334.50 | - | 5 | Mar 10, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | $85 → $80 | $77.46 | +3.28% | 40 | Feb 20, 2026 | |
| SNY Sanofi | Maintained: Buy | n/a | $44.29 | n/a | 17 | Jan 31, 2025 | |
| GSK GSK plc | Maintained: Sell | $1,415 | $51.38 | n/a | 23 | Dec 6, 2024 | |
| NVS Novartis AG | Rated: Hold | $118 → $130 | $152.01 | n/a | 17 | Sep 11, 2024 | |
| BME: GRF Grifols, S.A. | Initiated Coverage: Buy | $20 | $9.70 | n/a | 1 | Sep 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $358 → $8.28 | $343.80 | n/a | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $88 | $134.36 | n/a | 1 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $50 | $25.90 | n/a | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 | $53.38 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $26.88 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $3.29 | n/a | 1 | Oct 26, 2017 |
Novo Nordisk A/S
May 12, 2026
Maintained: Hold
Price Target: $275 → $290
Current: $289.00
Upside: +0.35%
GSK plc
May 6, 2026
Maintained: Hold
Price Target: $23 → $21
Current: $1,915.00
Upside: -98.90%
AstraZeneca PLC
Apr 30, 2026
Maintained: Buy
Price Target: n/a
Current: $13,916.00
Upside: -
Novartis AG
Apr 13, 2026
Maintained: Buy
Price Target: n/a
Current: $119.46
Upside: -
Roche Holding AG
Mar 10, 2026
Maintained: Buy
Price Target: n/a
Current: $334.50
Upside: -
Sanofi
Feb 20, 2026
Maintained: Hold
Price Target: $85 → $80
Current: $77.46
Upside: +3.28%
Sanofi
Jan 31, 2025
Maintained: Buy
Price Target: n/a
Current: $44.29
Upside: n/a
GSK plc
Dec 6, 2024
Maintained: Sell
Price Target: $1,415
Current: $51.38
Upside: n/a
Novartis AG
Sep 11, 2024
Rated: Hold
Price Target: $118 → $130
Current: $152.01
Upside: n/a
Grifols, S.A.
Sep 12, 2023
Initiated Coverage: Buy
Price Target: $20
Current: $9.70
Upside: n/a
Mar 7, 2023
Reiterated: Buy
Price Target: $358 → $8.28
Current: $343.80
Upside: n/a
Mar 3, 2023
Maintained: Hold
Price Target: $88
Current: $134.36
Upside: n/a
Feb 28, 2023
Maintained: Hold
Price Target: $50
Current: $25.90
Upside: n/a
Sep 10, 2018
Downgraded: Hold
Price Target: $34
Current: $53.38
Upside: n/a
Sep 10, 2018
Downgraded: Sell
Price Target: n/a
Current: $26.88
Upside: n/a
Oct 26, 2017
Downgraded: Sell
Price Target: n/a
Current: $3.29
Upside: n/a